Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart in AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627Phase 2Recruiting
- Sponsor
- argenx
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 6
01
Overview
A Phase 2 trial of empasiprubart in myasthenia gravis (MG), sponsored by argenx. Started Jul 2026; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07673627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673627.